CYP2S1 and thyroid cancer: Thus, we suppose that increased expression of CYP2S1 in BRAFV600E-mutated thyroid cancer cells lead to the concentration of certain metabolic products such as 12-HHT and 5-oxoETE, thereby promoting malignant phenotypes of cancer cells.